Premium
Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome
Author(s) -
Shimomura Yoshimitsu,
Hara Masahiko,
Tachibana Takayoshi,
Ohashi Kazuteru,
Sakura Toru,
Fukuda Takahiro,
Nakazawa Hideyuki,
Iwato Koji,
Kanda Yoshinobu,
Ikeda Takashi,
Eto Tetsuya,
Kanda Junya,
Ichinohe Tatsuo,
Atsuta Yoshiko,
Ishikawa Takayuki,
Ishiyama Ken
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15898
Subject(s) - medicine , hazard ratio , hematopoietic stem cell transplantation , transplantation , confidence interval , myelodysplastic syndromes , interquartile range , stem cell , international prognostic scoring system , oncology , bone marrow , biology , genetics
Summary Though second allogenic haematopoietic stem cell transplantation ( HSCT ) is considered a curative treatment option after myelodysplastic syndrome ( MDS ) relapse, scant epidemiological data are available. We investigated the outcomes and prognostic factors of second allogenic HSCT in 99 patients with MDS who relapsed after the first HSCT . The median age was 53 years (interquartile; 45–59) and 57 patients (57·6%) were male. Five‐year overall survival was 25·3%. Early relapse (adjusted hazard ratio: 2·78, 95% confidence interval: 1·08–7·21, P = 0·035) and poor performance (3·03, 1·71–5·37, P < 0·001) were associated with a significantly poor 5‐year overall survival compared to the other groups ( P < 0·001).